Good Law | Bad Law - The Cost of Drug Prices: A Conversation w/ Robert Field
08/02/19 • 37 min
Aaron Freiwald, Managing Partner of Freiwald Law and host of the weekly podcast, Good Law | Bad Law, is joined by Robert Field, a professor of health management and policy at the Dornsife School of Public Health as well as a law professor at Drexel University, to discuss drug pricing and drug pricing transparency.
Approximately 20 to 30 million people don’t have health insurance. Robert and Aaron sit down to talk about the complex system of bargaining that happens in our health care system, the staggering prices that drug companies charge for certain treatments, and the middle men who haggle co-pays to a “reasonable” amount compared to the original sticker-shock prices. Dr. Field explains how these companies control monopolies over assorted life-saving drugs because they’re under patents. Are there limits to how much drug companies can charge? What is the reach of authority over drug pricing?
Aaron and Robert delve into the world of health care and tackle a variety of topics. They consider the importance of “meaningful transparency,” as well as Trump’s recent failed initiative to shame drug manufacturers by mandating list prices be put on all TV drug ads. Listen in as Robert and Aaron talk about hospital stays, the evolution of our health care system, and much more. What are some ideas on how to address the problem of high drug prices? Is our current system efficient? How does our health care system compare to others around the world? Let us know what you think and listen now!
To learn more about Dr. Robert Field, check out his website here.
Host: Aaron Freiwald
Guest: Robert Field
Follow Good Law | Bad Law:
YouTube: Good Law | Bad Law
Instagram: @GoodLawBadLaw
Website: https://www.law-podcast.com
Aaron Freiwald, Managing Partner of Freiwald Law and host of the weekly podcast, Good Law | Bad Law, is joined by Robert Field, a professor of health management and policy at the Dornsife School of Public Health as well as a law professor at Drexel University, to discuss drug pricing and drug pricing transparency.
Approximately 20 to 30 million people don’t have health insurance. Robert and Aaron sit down to talk about the complex system of bargaining that happens in our health care system, the staggering prices that drug companies charge for certain treatments, and the middle men who haggle co-pays to a “reasonable” amount compared to the original sticker-shock prices. Dr. Field explains how these companies control monopolies over assorted life-saving drugs because they’re under patents. Are there limits to how much drug companies can charge? What is the reach of authority over drug pricing?
Aaron and Robert delve into the world of health care and tackle a variety of topics. They consider the importance of “meaningful transparency,” as well as Trump’s recent failed initiative to shame drug manufacturers by mandating list prices be put on all TV drug ads. Listen in as Robert and Aaron talk about hospital stays, the evolution of our health care system, and much more. What are some ideas on how to address the problem of high drug prices? Is our current system efficient? How does our health care system compare to others around the world? Let us know what you think and listen now!
To learn more about Dr. Robert Field, check out his website here.
Host: Aaron Freiwald
Guest: Robert Field
Follow Good Law | Bad Law:
YouTube: Good Law | Bad Law
Instagram: @GoodLawBadLaw
Website: https://www.law-podcast.com
Previous Episode
Good Law | Bad Law - The Ethics of Dying: A Conversation w/ Emily Largent
Aaron Freiwald, Managing Partner of Freiwald Law and host of the weekly podcast, Good Law | Bad Law, is joined by Emily Largent, a professor of medical ethics and health policy at the Perelman School of Medicine at Penn as well as a law professor at Penn Law, to discuss the issue of aid in dying – also known as, physician-assisted suicide.
New Jersey and Maine are set to become the 8th and 9th states with laws allowing physician-assisted suicide, subject to rigid rules and regulations. With this development, 70 million Americans will live in states where access to life-ending medication is available where a person has a confirmed terminal illness. Aaron and Dr. Largent discuss the legal and ethical issues raised by these laws. Dr. Largent explains that a patient might want to choose physician-assisted suicide in order to have the ability to make their own end-of-life decisions. Is it ethical to allow aided suicide to allow dignity in end-of-life care or is this a troubling development because doctors and others may participate in ending life rather than in making every effort to care for the sick and dying?
Emily and Aaron discuss many end-of-life care options, including doctor-assisted suicide, as well as other advanced directives like DNRs (Do Not Resuscitate orders), wills, and POAs (Power of Attorney orders.) Throughout the episode, Aaron and Emily consider the law and policy surrounding these choices, including the strict requirements associated with aid in dying options. Listen in as Aaron and Emily discuss these difficult decisions and as they explore the laws that make them available.
Host: Aaron Freiwald
Guest: Emily Largent
Follow Good Law | Bad Law:
YouTube: Good Law | Bad Law
Instagram: @GoodLawBadLaw
Website: https://www.law-podcast.com
Next Episode
Good Law | Bad Law - Busting Up Facebook and Amazon? A Conversation w/ Aaron Kershenbaum
Should mega-internet and social media companies like Facebook and Amazon be broken apart because they are just too big? Is it time to invoke the antitrust laws once again?
Aaron Freiwald, Managing Partner of Freiwald Law and host of the weekly podcast, Good Law | Bad Law, is joined by Dr. Aaron Kershenbaum, a former professor of electrical engineering and computer sciences at Brooklyn Polytechnic and an expert in digital communications, to discuss the AT&T antitrust lawsuit, and subsequent breakup, 35 years later as well as what may happen to today’s major communications and internet companies.
Having been one of the government’s key witnesses in the case against the tech giant, Dr. Kershenbaum explains his role in the influential AT&T lawsuit and his own experience in the world of communications. Aaron and Dr. Kershenbaum tackle some of today’s questions surrounding privacy, influence, regulation, and more in regards to some of the industry’s biggest names like Facebook, Amazon, and Instagram. How should we understand the breakup of AT&T 35 years after the fact? How did it impact today’s technology? And, what are the similarities between AT&T as a monopoly and companies like Amazon and Twitter today? Listen in as Aaron and Dr. Kershenbaum answer these questions and more.
Majoring in communications and graduating with a PhD in electrical engineering, Dr. Kershenbaum has spent a career in the digital communications field. Before his time in academia, Dr. Kershenbaum worked for Network Analysis Corporation and helped build the precursor to today’s internet, the ARPANET (Advanced Research Projects Agency Network), for the Department of Defense. He also spent time consulting for technology and communication companies like AT&T and IBM.
A fascinating conversation about history, innovation, and antitrust laws, today’s episode touches on many important topics and ideas that have not only shaped our world today but will continue to shape tomorrow.
Host: Aaron Freiwald
Guest: Aaron Kershenbaum
Follow Good Law | Bad Law:
YouTube: Good Law | Bad Law
Instagram: @GoodLawBadLaw
Website: https://www.law-podcast.com
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/good-law-bad-law-121025/good-law-bad-law-the-cost-of-drug-prices-a-conversation-w-robert-field-6140219"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to good law | bad law - the cost of drug prices: a conversation w/ robert field on goodpods" style="width: 225px" /> </a>
Copy